Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Multiple targeted treatments for FXS have rescued the phenotype of the fmr1 knockout mouse, but few have been beneficial to patients with FXS. The failure of the metabotropic glutamate receptor 5 antagonists falls on the heels of the failure of Arbaclofen's efficacy in children and adults with autism or FXS. In contrast, efficacy has been demonstrated in a controlled trial of minocycline in children with FXS. Minocycline lowers the abnormally elevated levels of matrix metalloproteinase 9 in FXS. Acamprosate and lovastatin have been beneficial in open-label trials in FXS. The first 5 years of life may be the most efficacious time for intervention when combined with behavioral and/or educational interventions. SUMMARY:
Minocycline, acamprosate, lovastatin, and sertraline are treatments that can be currently prescribed and have shown benefit in children with FXS. Use of combined medical and behavioral interventions will likely be most efficacious for the treatment of FXS.
|
Authors | Randi J Hagerman, Jonathan Polussa |
Journal | Current opinion in psychiatry
(Curr Opin Psychiatry)
Vol. 28
Issue 2
Pg. 107-12
(Mar 2015)
ISSN: 1473-6578 [Electronic] United States |
PMID | 25602250
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S., Review)
|
Chemical References |
- Taurine
- Lovastatin
- Minocycline
- Acamprosate
- Sertraline
|
Topics |
- Acamprosate
- Adult
- Animals
- Child
- Female
- Fragile X Syndrome
(drug therapy, psychology)
- Humans
- Lovastatin
(therapeutic use)
- Male
- Mice
- Minocycline
(therapeutic use)
- Sertraline
(therapeutic use)
- Taurine
(analogs & derivatives, therapeutic use)
|